new scrutiny of pharmacy compounding

December 2012

The fungal meningitis outbreak in the U.S. will result in new scrutiny of pharmacy compounding.

We all know that compounding fills several important needs.

But it gets confusing when a compounder acts like a manufacturer.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Vaccines more focus on proper vaccine storage
Anticoagulants The blood thinner Pradax (dabigatran) will now be called Pradaxa
Diabetes Meds two new tablet strengths of Januvia (sitagliptin)
Beta-Blockers changes in prescriptions for "beta-blockers" (propranolol, metoprolol, etc) being used for heart disease
Antidepressants There is continued confusion and mix-ups among bupropion forms
Interactions drug interaction alerts between methotrexate and "PPI" stomach acid reducers (omeprazole, pantoprazole, etc)
Fibromyalgia more emphasis on treating fibromyalgia
Side Effects more about bleeding with Pradaxa (dabigatran), Xarelto (rivaroxaban), and Eliquis (apixaban)
Gout rev up promotion of Uloric (febuxostat) for managing gout
Vaccines the safety of Agriflu and Fluad flu vaccines
Practice Hemocode test for food intolerance
Diabetes debate about whether diabetes patients who don't use insulin benefit from monitoring their blood sugar
Compounding new scrutiny of pharmacy compounding
Practice we hope you'll enjoy the holiday letter from our staff